GRAIL, Inc.
GRALHealthcareNASDAQDiagnostics & Research
Scan Results
Daily timeframeGRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. At a $3.53B market cap, GRAIL, Inc. ranks as a mid-cap company within healthcare. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients with clinical suspicion of cancer.
Market Cap
$3.53B
Beta
3.25
P/E (TTM)
—
P/E (Fwd)
-8.01
EPS (TTM)
$-9.69
EPS (Fwd)
$-9.87
ROE
-16.1%
ROA
-12.0%
Cash
$861.6M
Total Debt
$91.3M
Free CF
-$103.6M
52W Change
126.8%
Annual Financials
Cash vs Debt
Where GRAL stands vs its 150-day and 200-day moving averages
As of the August 24, 2026 close, GRAL finished 19.38% above its 150-day moving average ($66.63) and 8.51% above its 200-day moving average ($73.30). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is GRAL overbought or oversold?
At the August 24, 2026 close, GRAL's RSI(14) was 60.1, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $861.6M in cash and $91.3M in debt, GRAL maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow is running at -$103.6M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -16.1% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $55.5M (2022) to $147.2M (2025), reflecting a 165% increase over the period.
GRAIL, Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. With cash comfortably exceeding debt, GRAL has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing GRAL.